IMPROVES ENGAGEMENT, UPDATING AND RE-CONTACTING OF PATIENTS

PATIENT IDENTIFICATION & ELIGIBILITY

Patients who carry the variant your drug targets — or your plan should be managing — may already be flagged in health system records, but many have never been tested because no one confirmed their eligibility. My Gene Screen is a pre-test eligibility assessment that clinicians or patients can complete based on current guidelines. Embedding it inside partner health system and laboratory workflows identifies and qualifies the patient population your program depends on, before a test is ordered.

OFFERS HEALTHCARE PROVIDERS AND RESEARCHERS AND EASY WAY TO VIEW PATIENT GENETIC TEST DATA.

TRIAL RETENTION

Patient dropout is one of the most significant cost drivers in biomarker-selected clinical trials. Living Lab Reports® maintain a persistent, updating connection to enrolled patients — supporting retention, documenting engagement, and delivering informed consent content in a format that is measurable and reproducible for regulatory submissions. For health plans, the same infrastructure keeps members with hereditary findings informed and connected to appropriate care.

UNPARALLELED, IN-DEPTH SCIENTIFIC KNOWLEDGE RELATED TO GENETICS

LONGITUDINAL COHORT ENGAGEMENT

The value of a biomarker-defined cohort doesn’t end at trial completion — and a health plan’s obligation to members with hereditary findings doesn’t end at diagnosis. Genetic Alerts maintains your relationship with that population automatically, notifying patients and providers when classifications change, new evidence emerges, or new indications become available. For pharmaceutical and payer organizations alike, this is the infrastructure that turns a one-time interaction into a persistent, updatable patient relationship.

BIOPHARMA, CLINICAL TRIALS & PAYERS

Your program depends on patients who carry a specific genetic variant.

Our products help your clinical partners identify patients, activate them, and keep them engaged as science evolves.

My Gene Counsel brings three integrated engines to pharmaceutical programs, clinical trials, and health plans: My Gene Screen identifies patients who carry the variant your therapy targets or your plan should be managing, Living Lab Reports® educate and retain them through trial participation or post-diagnosis care, and Genetic Alerts maintain longitudinal engagement with your biomarker-defined cohort — or your member population — as evidence and classifications evolve.

My Gene Counsel meets the urgent need for a scalable patient-centric digital counseling tool to follow patients over time in the post-test period, effectively translating genome science at the patient, provider and system levels.

Gillian Hooker

PhD, ScM Genetic Counseling